Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 2
1998 5
1999 13
2000 22
2001 66
2002 59
2003 65
2004 76
2005 107
2006 53
2007 58
2008 86
2009 74
2010 99
2011 82
2012 93
2013 91
2014 84
2015 84
2016 80
2017 71
2018 68
2019 76
2020 81
2021 80
2022 86
2023 4
Text availability
Article attribute
Article type
Publication date

Search Results

1,641 results
Results by year
Filters applied: . Clear all
Page 1
Basiliximab for steroid-refractory acute graft-versus-host disease: A real-world analysis.
Mo XD, Hong SD, Zhao YL, Jiang EL, Chen J, Xu Y, Sun ZM, Zhang WJ, Liu QF, Liu DH, Wan DM, Mo WJ, Ren HY, Yang T, Huang H, Zhang X, Wang XN, Song XM, Gao SJ, Wang X, Chen Y, Xu B, Jiang M, Huang XB, Li X, Zhang HY, Wang HT, Wang Z, Niu T, Wang JS, Xia LH, Liu XD, Li F, Zhou F, Lang T, Hu J, Wu SJ, Huang XJ. Mo XD, et al. Am J Hematol. 2022 Apr;97(4):458-469. doi: 10.1002/ajh.26475. Epub 2022 Feb 4. Am J Hematol. 2022. PMID: 35064928
Basiliximab was used as monotherapy (n = 642) or in combination with other second-line treatments (n = 298). ...Thus, real-world data suggest that basiliximab is safe and effective for treating SR-aGVHD....
Basiliximab was used as monotherapy (n = 642) or in combination with other second-line treatments (n = 298). ...Thus, real-world data …
Basiliximab.
Onrust SV, Wiseman LR. Onrust SV, et al. Drugs. 1999 Feb;57(2):207-13; discussion 214. doi: 10.2165/00003495-199957020-00006. Drugs. 1999. PMID: 10188761 Review.
This level of basiliximab binding was maintained for 4 to 6 weeks when renal transplant patients received basiliximab 20 mg 2 hours before and then 4 days after transplantation surgery. ...Cytokine release syndrome was not observed in patients who received basili …
This level of basiliximab binding was maintained for 4 to 6 weeks when renal transplant patients received basiliximab 20 mg 2 …
Basiliximab Does Not Impair Airway Mucociliary Clearance of Rats.
Correia AT, de Almeida FM, Augusto-Cottet MC, Nolasco P, Bento ASA, Hirano HKM, de Souza MCR, Dos Santos ES, de Castro JHR, Matsuda M, Pêgo-Fernandes PM, Pazetti R. Correia AT, et al. Inflammation. 2022 Dec;45(6):2243-2255. doi: 10.1007/s10753-022-01687-0. Epub 2022 Jun 17. Inflammation. 2022. PMID: 35715590
Previous studies have shown that immunosuppressive drugs impair the airway mucociliary clearance of rats. However, considering the high specificity of basiliximab (BSX) and the absence of studies reporting its side effects, our aim was to investigate whether BSX, associate …
Previous studies have shown that immunosuppressive drugs impair the airway mucociliary clearance of rats. However, considering the high spec …
Basiliximab: a review of its use as induction therapy in renal transplantation.
Chapman TM, Keating GM. Chapman TM, et al. Drugs. 2003;63(24):2803-35. doi: 10.2165/00003495-200363240-00009. Drugs. 2003. PMID: 14664658 Review.
Rare cases of hypersensitivity reactions to basiliximab have been reported. The efficacy of basiliximab was similar to that of equine antithymocyte globulin (ATG) and daclizumab, and similar to or greater than that of muromonab CD3. ...Basiliximab did not inc …
Rare cases of hypersensitivity reactions to basiliximab have been reported. The efficacy of basiliximab was similar to that of …
Induction therapy of basiliximab versus antithymocyte globulin in renal allograft: a systematic review and meta-analysis.
Wang K, Xu X, Fan M. Wang K, et al. Clin Exp Nephrol. 2018 Jun;22(3):684-693. doi: 10.1007/s10157-017-1480-z. Epub 2017 Oct 6. Clin Exp Nephrol. 2018. PMID: 28986715 Review.
OBJECTIVE: The aim of this meta-analysis was to evaluate the efficacy of basiliximab versus antithymocyte globulin for induction therapy in renal allograft. ...However, regarding the long-term effect, as represented by the rate of neoplasm, basiliximab has a signifi …
OBJECTIVE: The aim of this meta-analysis was to evaluate the efficacy of basiliximab versus antithymocyte globulin for induction ther …
124I Radiolabeled Basiliximab for CD25-Targeted Immuno-PET Imaging of Activated T Cells.
Wang S, Liu F, Wang P, Wen L, Wang Z, Guo Q, Zhu H, Yang Z. Wang S, et al. Mol Pharm. 2022 Jul 4;19(7):2629-2637. doi: 10.1021/acs.molpharmaceut.2c00330. Epub 2022 Jun 15. Mol Pharm. 2022. PMID: 35704773
In this paper, by utilizing the long half-life radionuclide iodine-124 ((124)I) and CD25 specific monoclonal antibody Basiliximab, we have fabricated a novel probe, namely, (124)I-Basiliximab, which was highly promising in the immuno-PET imaging of T cells. ...More …
In this paper, by utilizing the long half-life radionuclide iodine-124 ((124)I) and CD25 specific monoclonal antibody Basiliximab, we …
Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial.
Zhao K, Lin R, Fan Z, Chen X, Wang Y, Huang F, Xu N, Zhang X, Zhang X, Xuan L, Wang S, Lin D, Deng L, Nie D, Weng J, Li Y, Zhang X, Li Y, Xiang AP, Liu Q. Zhao K, et al. J Hematol Oncol. 2022 Mar 7;15(1):22. doi: 10.1186/s13045-022-01240-4. J Hematol Oncol. 2022. PMID: 35255929 Free PMC article. Clinical Trial.
We aimed to assess the efficacy and safety of MSCs combined with basiliximab and calcineurin inhibitor as second-line therapy for SR aGVHD. ...
We aimed to assess the efficacy and safety of MSCs combined with basiliximab and calcineurin inhibitor as second-line therapy for SR …
Basiliximab, mechanism of action and pharmacological properties.
Kapic E, Becic F, Kusturica J. Kapic E, et al. Med Arh. 2004;58(6):373-6. Med Arh. 2004. PMID: 15648237 Review.
Basiliximab is a chimeric anti-intcrleukin-2 receptor monoclonal antibody. Basiliximab is a glycoprotein produced by recombinant technology. It is used to prevent white blood cells from acute renal transplantation rejection. ...
Basiliximab is a chimeric anti-intcrleukin-2 receptor monoclonal antibody. Basiliximab is a glycoprotein produced by recombina …
Basiliximab Induction with Delayed Calcineurin Inhibitors for High-Risk Lung Transplant Candidates.
Kim HE, Paik HC, Jeong SJ, Park MS, Kim SY, Lee JG. Kim HE, et al. Yonsei Med J. 2021 Feb;62(2):164-171. doi: 10.3349/ymj.2021.62.2.164. Yonsei Med J. 2021. PMID: 33527796 Free PMC article.
To date, there is no consensus regarding the optimal agent for the induction regimen after lung transplantation. We aimed to determine the efficacy of basiliximab induction with delayed CNI initiation in the prevention of acute complications without compromising immunosupp …
To date, there is no consensus regarding the optimal agent for the induction regimen after lung transplantation. We aimed to determine the e …
1,641 results

Searches related to "basiliximab"